2. (Amended) A composition [Micelles or micro-aggregates] according to claim 1 [characterized in that] wherein the lipopeptides independently comprise one or more $C_4$-$C_{18}$ lipid units.

Sub D2

3. (Amended) A composition [Micelles or micro-aggregates] according to [one of claims 1 and 2] Claim 1 [characterized in that] wherein the lipopeptides independently comprise one or two $C_4$-$C_{18}$ lipid chains linked by a covalent bond to one or two amino acids of the peptide part.

Cont A'

4. (Amended) A composition [Micelles or micro-aggregates] according to [one of claims 1 to 3] Claim 1 [characterized in that] wherein the lipid units of the lipopeptides are composed of two palmitic acid chains linked to the $NH_2$ groups of a lysine.

5. (Amended) A composition [Micelles or micro-aggregates] according to [one of claims 1 to 4] Claim 1 [characterized in that] wherein the lipid units of the lipopeptides independently comprise a residue of palmitic acid, 2-aminohexadecanoic acid, oleic acid, linoleic acid, linolenic acid, pimelautide, trimexautide, or a derivative of cholesterol.

6. (Amended) A composition [Micelles or micro-aggregates] according to [one of claims 1 to 5] Claim 1 [characterized in that] wherein the non-lipid part of the lipopeptides, comprising the antigenic determinant, comprises between 10 and 100[, and preferably between 10 and 50] amino acids.

7. (Amended) A composition [Micelles or micro-aggregates] according to [one of claims 1 to 6] Claim 1 [characterized in that] wherein the helper T antigenic determinant is a multivalent antigenic determinant.

8. (Amended) A composition [Micelles or micro-aggregates] according to [one of claims 1 to 7] Claim 1 [characterized in that] wherein the helper T antigenic determinant is the peptide 830-843 of the tetanus toxin with the following sequence:

B

QYIKANSKFIGITE (SEQ ID NO:1)

9. (Amended) A composition [Micelles or micro-aggregates] according to [one of claims 1 to 7] Claim 1 [characterized in that] wherein the helper T antigenic determinant is the antigenic determinant of hemagglutinin or the PADRE antigenic determinant.

Sub. D3

10. (Amended) A composition [Micelles or micro-aggregates] according to [one of claims 1 to 9] Claim 1 [characterized in that] wherein the lipopeptides comprise at least one CTL antigenic determinant selected from the group consisting of a specific protein of melanoma, of a protein from HIV, from HBV, from papillomavirus, or protein p53, or a specific protein of *Plasmodium falciparum*.

Cont A1

11. (Amended) A composition [Micelles or micro-aggregates] according to [one of claims 1 to 10] Claim 1 [characterized in that they] wherein said micelles or micro-aggregates comprise the following lipopeptides:

| | | |
|---|---|---|
| B | GAG 17 | EKIRLRPGGKKKYKLKHIVK(Pam)-$NH_2$ (SEQ ID NO:31) |
| B | GAG 253 | NPPIPVGEIYKRWIILGLNKIVRMYSPTSILDK(Pam)-$NH_2$ (SEQ ID NO:6) |
| B | POL 325 | AIFQSSMTKILEPFRKQNPDIVIYQYMDDLYK(Pam)-$NH_2$ (SEQ ID NO:32) |
| B | NEF 66 | VGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLK(Pam)-$NH_2$ (SEQ ID NO. 2) |
| B | NEF 116 | HTQGYFPDWQNYTPGPGVRYPLTFGWLYKLK(Pam)-$NH_2$ (SEQ ID NO. 33) |
| B | TT | Ac-QYIKANSKFIGITELKKK(Pam)-$NH_2$ (SEQ ID NO: 34) |

12. (Amended) A composition [Micelles or micro-aggregates] according to [one of claims 1 to 10] Claim 1 [characterized in that they] wherein said micelles or micro-aggregates comprise the following lipopeptides:

| | | |
|---|---|---|
| B | LSA3 CT1 | LLSNIEEPKENIIDNLLNNIK(Pam)-$NH_2$ (SEQ ID NO. 34) |
| B | LSA3 NR1 | Ac-DELFNELLNSVDVNGEVKENILEESQK(Pam)-$NH_2$ (SEQ ID NO: 35) |
| B | LSA3 NRII | Ac-LEESQVNDDIFNSLVKSVQQEQQHNVK(Pam)-$NH_2$ (SEQ ID NO: 36) |
| B | LSA3 RE | K(Pam)VESVAPSVEESVAPSVEESVAENVEESVAENV-$NH_2$ (SEQ ID NO: 37) |

Sub. D4

13. (Amended) A method [Use of micelles or micro-aggregates according to one of claims 1 to 12] for the production of a drug or a vaccine for inducing a specific immune response comprising micelles or micro-aggregates according to Claim 1.

14. (Amended) A method according to Claim 13 wherein said [Use of micelles or micro-aggregates according to one of claims 1 to 12 for the production of a drug or a vaccine for inducing a] specific immune response is against HIV, HBV, papillomavirus, p53, melanoma or malaria induced by *Plasmodium falciparum*.

Sub.D4

15. (Amended) A pharmaceutical [Pharmaceutical] composition [characterized in that it comprises] comprising a pharmacologically effective dose of micelles or micro-aggregates according to [one of claims 1 to 12] Claim 1 and pharmaceutically compatible vehicles.

Cont a'

16. (Amended) A drug [Drug] or vaccine [characterized in that it comprises] comprising micelles or micro-aggregates according to [one of claims 1 to 12] Claim 1.

17. (Amended) A method [Method] for producing micelles or micro-aggregates according to [one of claims 1 to 12] Claim 1, comprising the following steps:

- [dispersion of] dispersing each of the constituent lipopeptides in a solution of concentrated acetic acid of about 80% concentration then
- mixing the solutions thus obtained.

Sub.D5

18. (Amended) A method [Method] according to Claim 17 [characterized in that] wherein the [production of a dispersion] dispersing of the lipopeptides dissolved in acetic acid is controlled by [the] a two-dimensional nuclear magnetic resonance method.

19. (Amended) A method [Method] for inducing an immune response against a particular antigen comprising at least the administration of micelles or micro-aggregates according to [one of claims 1 to 12] Claim 1 to an individual for whom such a response is desired.

20. (Amended) A method [Method] of immunization against a pathogenic agent comprising the administration of micelles or micro-aggregates according to [one of claims 1 to 12] Claim 1 to an individual for whom such an immunization is sought.

21. (Amended) A method [Method] according to [one of claims 19 and 20] Claim 19, [characterized in that] wherein the pathogenic agent is HIV, HBV, papillomavirus, melanoma or *plasmodium falciparum*, and wherein the antigen is an antigen of one of [these] said pathogenic agents, or p53.

Please add the following new claims:

--22. A composition according to Claim 1, wherein the at least one lipid unit in the second lipopeptide is different from the at least one lipid unit in the first lipopeptide.

23. A composition according to Claim 6, wherein the non-lipid part of the lipopeptides, comprising the antigenic determinants, comprises between 10 and 50 amino acids.

24. A method according to Claim 20, wherein the pathogenic agent is HIV, HBV, papillomavirus, melanoma, or *Plasmodium falciparum*, and wherein the antigen is an antigen of one of said pathogenic agents, or p53.--

## REMARKS

Applicant respectfully requests entry of this Preliminary Amendment prior to examination on the merits of the National Stage PCT Application filed herewith. This Amendment rewrites the claims in a more traditional U.S. format and removes multiple dependencies. The new claims are dependent claims that contain matter included in the claims as originally filed. No new matter has been added.